Division of Conmed Corp.
Latest From ConMed Corp.
Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.
Global sales for arthroscopy and sports medicine devices are predicted to hit $6.5bn by 2021. This will be driven by the fast-growing soft tissue fixation products segment: significant changes in market dynamics are expected over the next few years, as hip fixation procedures pick up pace. This article delves into the landscape of the soft tissue fixation device market, as well as the four key segments in the arthroscopy devices space. It will also analyze the key players in these markets, highlight trends and discuss the biggest challenges.
Story and Podcast: Teleflex Medical launched in March a novel portfolio of miniaturized percutaneous surgical instruments that have the same functionality as full-sized laparoscopic instruments, but allow surgeons to access the abdominal cavity using trocar-less entry and much smaller incisions than those required in traditional laparoscopy. Teleflex execs say the technology is a game changer, and the company hopes percutaneous laparoscopy will become the standard of care for the 4 million laparoscopic procedures performed annually in the US.
At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Gynecological, Urological
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Conmed Corp.
- ConMed Corp.
- Senior Management
Curt Hartman, CEO
Luke Pomilio, EVP, Fin. & CFO
Mark R Donovan, VP, Global Corp. Mktg.
Peter Shagory, EVP, Strategy & Corp. Dev.
- Contact Info
Phone: (315) 797-8375
525 French Rd.
Utica, NY 13502
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.